Breaking News

Samsung Biologics, Checkpoint Therapeutics Expand Cosibelimab Mfg. Pact

Samsung Biologics will provide additional commercial-scale drug substance manufacturing.

By: Contract Pharma

Contract Pharma Staff

Samsung Biologics and Checkpoint Therapeutics, Inc. have expanded a long-term manufacturing partnership for Checkpoint’s anti-PD-L1 antibody, cosibelimab. Building upon an existing contract manufacturing agreement entered into in 2017, Samsung Biologics will provide additional commercial-scale drug substance manufacturing for Checkpoint and will begin manufacturing in 2021 in Plant 1. “We look forward to continuing our manufacturing partnership with Samsung Biologics for our lead ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters